Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback